245 related articles for article (PubMed ID: 37955637)
1. Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma.
Sarkari A; Korenfeld S; Deniz K; Ladner K; Wong P; Padmanabhan S; Vogel RI; Sherer LA; Courtemanche N; Steer C; Wainer-Katsir K; Lou E
Elife; 2023 Nov; 12():. PubMed ID: 37955637
[TBL] [Abstract][Full Text] [Related]
2. Intercellular communication in malignant pleural mesothelioma: properties of tunneling nanotubes.
Ady JW; Desir S; Thayanithy V; Vogel RI; Moreira AL; Downey RJ; Fong Y; Manova-Todorova K; Moore MA; Lou E
Front Physiol; 2014; 5():400. PubMed ID: 25400582
[TBL] [Abstract][Full Text] [Related]
3.
Lou E
Front Oncol; 2020; 10():559548. PubMed ID: 33324545
[TBL] [Abstract][Full Text] [Related]
4. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
Mumblat H; Martinez-Conde A; Braten O; Munster M; Dor-On E; Schneiderman RS; Porat Y; Voloshin T; Davidi S; Blatt R; Shteingauz A; Tempel-Brami C; Zeevi E; Lajterer C; Shmueli Y; Danilov S; Haber A; Giladi M; Weinberg U; Kinzel A; Palti Y
Lung Cancer; 2021 Oct; 160():99-110. PubMed ID: 34482104
[TBL] [Abstract][Full Text] [Related]
5. Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations.
Mannarino L; Mirimao F; Panini N; Paracchini L; Marchini S; Beltrame L; Amodeo R; Grosso F; Libener R; De Simone I; Ceresoli GL; Zucali PA; Lupi M; D'Incalci M
Cell Death Dis; 2022 Jul; 13(7):612. PubMed ID: 35840560
[TBL] [Abstract][Full Text] [Related]
6. Tumor exosomes induce tunneling nanotubes in lipid raft-enriched regions of human mesothelioma cells.
Thayanithy V; Babatunde V; Dickson EL; Wong P; Oh S; Ke X; Barlas A; Fujisawa S; Romin Y; Moreira AL; Downey RJ; Steer CJ; Subramanian S; Manova-Todorova K; Moore MAS; Lou E
Exp Cell Res; 2014 Apr; 323(1):178-188. PubMed ID: 24468420
[TBL] [Abstract][Full Text] [Related]
7. A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights.
Li X; Liu K; Xing L; Rubinsky B
Radiol Oncol; 2023 Sep; 57(3):279-291. PubMed ID: 37665740
[TBL] [Abstract][Full Text] [Related]
8. Macrophages enhance 3D invasion in a breast cancer cell line by induction of tumor cell tunneling nanotubes.
Carter KP; Hanna S; Genna A; Lewis D; Segall JE; Cox D
Cancer Rep (Hoboken); 2019 Dec; 2(6):e1213. PubMed ID: 32467880
[TBL] [Abstract][Full Text] [Related]
9. Pseudorabies Virus US3-Induced Tunneling Nanotubes Contain Stabilized Microtubules, Interact with Neighboring Cells via Cadherins, and Allow Intercellular Molecular Communication.
Jansens RJJ; Van den Broeck W; De Pelsmaeker S; Lamote JAS; Van Waesberghe C; Couck L; Favoreel HW
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747498
[TBL] [Abstract][Full Text] [Related]
10. An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications.
Karanam NK; Story MD
Int J Radiat Biol; 2021; 97(8):1044-1054. PubMed ID: 33086019
[TBL] [Abstract][Full Text] [Related]
11. Tunneling Nanotubes between Cells Migrating in ECM Mimicking Fibrous Environments.
Jana A; Ladner K; Lou E; Nain AS
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454893
[TBL] [Abstract][Full Text] [Related]
12. Real-Time Monitoring of the Effect of Tumour-Treating Fields on Cell Division Using Live-Cell Imaging.
Le HT; Staelens M; Lazzari D; Chan G; Tuszyński JA
Cells; 2022 Aug; 11(17):. PubMed ID: 36078119
[TBL] [Abstract][Full Text] [Related]
13. The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy.
Tanzhu G; Chen L; Xiao G; Shi W; Peng H; Chen D; Zhou R
Cell Death Discov; 2022 Oct; 8(1):416. PubMed ID: 36220835
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-Induced Tunneling Nanotubes Mediate Intercellular Drug Efflux in Pancreatic Cancer.
Desir S; O'Hare P; Vogel RI; Sperduto W; Sarkari A; Dickson EL; Wong P; Nelson AC; Fong Y; Steer CJ; Subramanian S; Lou E
Sci Rep; 2018 Jun; 8(1):9484. PubMed ID: 29930346
[TBL] [Abstract][Full Text] [Related]
15. Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.
Wang Y; Pandey M; Ballo MT
Oncologist; 2019 Dec; 24(12):e1426-e1436. PubMed ID: 31444292
[TBL] [Abstract][Full Text] [Related]
16. Identification and Characterization of Tunneling Nanotubes for Intercellular Trafficking.
Sáenz-de-Santa-María I; Henderson JM; Pepe A; Zurzolo C
Curr Protoc; 2023 Nov; 3(11):e939. PubMed ID: 37994667
[TBL] [Abstract][Full Text] [Related]
17. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
18. Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma.
Kutuk T; Walker JM; Ballo MT; Cameron RB; Alvarez JB; Chawla S; Luk E; Behl D; Dal Pra A; Morganstein N; Refaat T; Sheybani A; Squillante C; Zhang J; Kotecha R
Curr Oncol; 2023 May; 30(6):5195-5200. PubMed ID: 37366877
[TBL] [Abstract][Full Text] [Related]
19. Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Acting Dynamics.
Voloshin T; Schneiderman RS; Volodin A; Shamir RR; Kaynan N; Zeevi E; Koren L; Klein-Goldberg A; Paz R; Giladi M; Bomzon Z; Weinberg U; Palti Y
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33080774
[TBL] [Abstract][Full Text] [Related]
20. Tumor treating fields: narrative review of a promising treatment modality for cancer.
Kutuk T; Atak E; La Rosa A; Kotecha R; Mehta MP; Chuong MD
Chin Clin Oncol; 2023 Dec; 12(6):64. PubMed ID: 37953242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
